anti-HER2 monoclonal antibody BAT1006

A glycosylation engineered recombinant humanized monoclonal antibody targeting the extracellular dimerization domain (subdomain II) of the tumor-associated antigen (TAA) and tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody BAT1006 targets and binds to HER2 on tumor cells, thereby blocking HER2-mediated signaling. This may inhibit the proliferation of HER2-expressing tumor cells. In addition, BAT1006 induces antibody-dependent cell-mediated cytotoxicity (ADCC). HER2, overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation, differentiation and survival.